RESEARCH MONOGRAPH · KDC-MN-040

Rolziracetam

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

24/100

Obscure bicyclic racetam with almost no modern literature, mostly historical

Rolziracetam is one of the deeper cuts on the racetam family tree. The bicyclic pyrrolidinone structure puts it in a similar architectural space as dimiracetam and a few other ring-fused variants, but the literature on it is genuinely thin. Most of the published work dates to the 80s and early 90s, mostly out of European medicinal chemistry programs that never advanced to serious clinical development.

What we know structurally is that the ring-fusion changes the conformational profile compared to standard piracetam-family compounds in ways that probably matter for receptor interaction. What we dont know is what the primary target actually is. The handful of papers that exist describe activity in passive avoidance and Morris water maze models in aged rats, but the receptor pharmacology was never properly characterized. So you're left with a molecule that has some signal in behavioral models and no clear mechanism.

Honestly, we havent run this one in lab and wouldnt try to convince anyone its a research priority. The literature is too thin to recommend it for anything specific.

What we like: structurally novel within the racetam family, scaffold curiosity value for medicinal chemists, and the conformational rigidity introduced by the bicyclic core makes it potentially useful for SAR work on what parts of the racetam pharmacophore actually matter.

What we dont like: essentially everything else. No modern data, no replicated behavioral effects, no clear receptor profile, and vendor availability that ranges from poor to nonexistent.

Sourcing this compound is a real problem. Few suppliers carry it, those that do often have limited characterization data, and impurity profiles are not well-published. If you're going to use it for anything, mass-spec verification is essentially mandatory, and even then you may struggle to find a reference standard.

This is honestly one we'd skip unless you've got a specific medicinal chemistry reason to want this exact scaffold. The opportunity cost versus running similar work with better-characterized racetams is high.

Pure historical interest, basically. Not a working tool.

Evidence: 15
Mechanism: 25
Reliability: 20
Safety: 45
Sourcing: 25
Value: 30
Signal: 15
Staying power: 20

Plain-language summary Intrigue 25 / 100

Rolziracetam is a bicyclic pyrrolidinone racetam. Research compound with limited published clinical data. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Bicyclic pyrrolidinone racetam

A bicyclic piracetam analog with sparse published literature; primarily of historical and research-chemical interest.

Abstract

Rolziracetam is a bicyclic racetam analog with sparse published literature and no clinical development record. The compound features a fused bicyclic scaffold built on the pyrrolidinone core. Mechanism is presumed to overlap with piracetam pharmacology but has not been formally characterized. The compound is occasionally available from research chemical vendors; identity confirmation by mass spectrometry is essential before any investigational use. There is no published human pharmacokinetic data, no Phase 1 safety record, and no peer-reviewed dose-finding studies. This entry is included for completeness of the racetam class survey and as a marker that "racetam" as a class label spans well-characterized compounds (piracetam, levetiracetam) and obscure analogs with thin evidence bases.

Mechanism of action

Presumed overlap with piracetam; no formal characterization.

Reported research dose ranges

No reliable data.

References

No substantial peer-reviewed published references for this specific analog.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-040

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Rolziracetam

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs